Oncolytics reports interim results from Phase 1/2 GOBLET study

Oncolytics Biotech (ONCY) reported interim results from the phase 1/2 GOBLET study’s first-line advanced/metastatic pancreatic ductal adenocarcinoma cohort in an abstract published as part of the Society for Immunotherapy of Cancer 37th Annual Meeting. As of the abstract’s data cutoff date, July 28, 2022, seven of ten evaluable patients in GOBLET’s PDAC cohort, which evaluates pelareorep in combination with Roche’s (RHHBY) anti-PD-L1 checkpoint inhibitor atezolizumab and the chemotherapeutic agents gemcitabine and nab-paclitaxel, achieved a partial response (3 confirmed, 4 unconfirmed as of the cutoff date). An additional two patients achieved stable disease for an ORR and clinical benefit rate of 70% and 90%, respectively. No safety signals were observed with the studied combination.